{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:35:35Z","timestamp":1791182135720,"version":"4.1.0"},"reference-count":48,"publisher":"Portland Press Ltd.","issue":"5","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10,1]]},"abstract":"<jats:p>Elafin is an endogenous human protein composed of an N-terminal transglutaminase substrate motif and a C-terminal WAP (whey acidic protein)-domain with antiproteolytic properties. Elafin is expressed predominantly in epithelial tissue and potently inhibits the neutrophil-derived serine proteases elastase and proteinase-3 by a competitive tight-binding mechanism. Furthermore, it inhibits EVE (endogenous vascular elastase). Studies on several animal models show that antiprotease augmentation with human elafin is an effective strategy in the treatment of inflammatory vascular, systemic and pulmonary diseases and of inflammation triggered by reperfusion injury. This raises the possibility that elafin might be effective in the treatment of a variety of human inflammatory diseases. In a Phase I clinical trial, elafin was well tolerated. Phase II trials are underway to investigate the therapeutic effects of elafin on post-operative inflammation and the clinical consequences of major surgery. Of particular interest is the reduction of post-operative morbidity after oesophagus cancer surgery, coronary artery bypass surgery and kidney transplantation.<\/jats:p>","DOI":"10.1042\/bst0391450","type":"journal-article","created":{"date-parts":[[2012,5,3]],"date-time":"2012-05-03T12:32:44Z","timestamp":1336048364000},"page":"1450-1454","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Therapeutic potential of human elafin"],"prefix":"10.1042","volume":"39","author":[{"given":"Lee","family":"Shaw","sequence":"first","affiliation":[{"name":"Proteo Biotech AG, Am-Kiel-Kanal 44, 24106 Kiel, Germany"},{"name":"Institute of Biochemistry, University of Kiel, Olshausenstrasse 40, 24098 Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Wiedow","sequence":"additional","affiliation":[{"name":"Proteo Biotech AG, Am-Kiel-Kanal 44, 24106 Kiel, Germany"},{"name":"Department of Dermatology, University of Kiel, Schittenhelmstrasse 7, 24105 Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2011,9,21]]},"reference":[{"key":"2021111900514075900_B1","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1172\/JCI118926","article-title":"Constitutive and inducible expression of SKALP\/elafin provides anti-elastase defense in human epithelia","volume":"98","author":"Pfundt","year":"1996","journal-title":"J. Clin. Invest."},{"key":"2021111900514075900_B2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2567.2009.03165.x","article-title":"Trappin-2\/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract","volume":"129","author":"Ghosh","year":"2010","journal-title":"Immunology"},{"key":"2021111900514075900_B3","first-page":"27","article-title":"Isolation of elafin and elastase-specific inhibitor (ESI) from bronchial secretions: evidence of sequence homology and immunological cross-reactivity","volume":"373","author":"Sallenave","year":"1992","journal-title":"Biol. Chem."},{"key":"2021111900514075900_B4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s004030050475","article-title":"TNF-\u03b1 and serum induce SKALP\/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway","volume":"292","author":"Pfundt","year":"2000","journal-title":"Arch. Dermatol. Res."},{"key":"2021111900514075900_B5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/1523-1747.ep12612749","article-title":"Levels of skin-derived antileukoproteinase (SKALP)\/elafin in serum correlate with disease activity during treatment of severe psoriasis with cyclosporin A","volume":"104","author":"Alkemade","year":"1995","journal-title":"J. Invest. Dermatol."},{"key":"2021111900514075900_B6","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1165\/rcmb.2008-0410OC","article-title":"Genetic polymorphisms of peptidase inhibitor 3 (elafin) are associated with acute respiratory distress syndrome","volume":"41","author":"Tejera","year":"2009","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"2021111900514075900_B7","doi-asserted-by":"crossref","first-page":"14791","DOI":"10.1016\/S0021-9258(18)77182-2","article-title":"Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence","volume":"265","author":"Wiedow","year":"1990","journal-title":"J. Biol. Chem."},{"key":"2021111900514075900_B8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0925-4439(91)90053-C","article-title":"Skin-derived antileukoproteinase (SKALP, an elastase inhibitor from human keratinocytes: purification and biochemical properties","volume":"1096","author":"Schalkwijk","year":"1991","journal-title":"Biochim. Biophys. Acta"},{"key":"2021111900514075900_B9","doi-asserted-by":"crossref","first-page":"11570","DOI":"10.1021\/bi960900l","article-title":"Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 \u00c5 resolution","volume":"35","author":"Tsunemi","year":"1996","journal-title":"Biochemistry"},{"key":"2021111900514075900_B10","doi-asserted-by":"crossref","first-page":"15610","DOI":"10.1021\/bi051418i","article-title":"Elafin and its precursor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase","volume":"44","author":"Guyot","year":"2005","journal-title":"Biochemistry"},{"key":"2021111900514075900_B11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/0006-291X(91)90476-N","article-title":"Elafin is a potent inhibitor of proteinase 3","volume":"174","author":"Wiedow","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021111900514075900_B12","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1021\/bi00058a021","article-title":"Kinetics of the inhibition of human leukocyte elastase by elafin, a 6-kilodalton elastase-specific inhibitor from human skin","volume":"32","author":"Ying","year":"1993","journal-title":"Biochemistry"},{"key":"2021111900514075900_B13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1165\/ajrcmb.24.1.4300","article-title":"Kinetics of the inhibition of proteinase 3 by elafin","volume":"24","author":"Ying","year":"2001","journal-title":"Am. J. Respir Cell. Mol. Biol."},{"key":"2021111900514075900_B14","doi-asserted-by":"crossref","first-page":"L5","DOI":"10.1152\/ajplung.1999.277.1.L5","article-title":"EVE and beyond, retro and prospective insights","volume":"277","author":"Rabinovitch","year":"1999","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"2021111900514075900_B15","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1172\/JCI118692","article-title":"Elafin, a serine elastase inhibitor, attenuates post-cardiac transplant coronary arteriopathy and reduces myocardial necrosis in rabbits after heterotopic cardiac transplantation","volume":"97","author":"Cowan","year":"1996","journal-title":"J. Clin. Invest."},{"key":"2021111900514075900_B16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1042\/bj3400569","article-title":"The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core","volume":"340","author":"Schalkwijk","year":"1999","journal-title":"Biochem. J."},{"key":"2021111900514075900_B17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0006-291X(92)91721-2","article-title":"Synthesis and structure-activity relationships of elafin, an elastase-specific inhibitor","volume":"185","author":"Tsunemi","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021111900514075900_B18","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/BF00371734","article-title":"Lesional elastase activity in psoriasis: diagnostic and prognostic significance","volume":"287","author":"Wiedow","year":"1995","journal-title":"Arch. Dermatol. Res."},{"key":"2021111900514075900_B19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.0022-202x.2001.01650.x","article-title":"Human leukocyte elastase induces keratinocyte proliferation in vitro and in vivo","volume":"118","author":"Rogalski","year":"2002","journal-title":"J. Invest. Dermatol."},{"key":"2021111900514075900_B20","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.0022-202X.2004.23202.x","article-title":"Human leukocyte elastase induces keratinocyte proliferation by epidermal growth factor receptor activation","volume":"123","author":"Meyer-Hoffert","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"2021111900514075900_B21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/hc0402.102866","article-title":"Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension","volume":"105","author":"Zaidi","year":"2002","journal-title":"Circulation"},{"key":"2021111900514075900_B22","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1172\/JCI9147","article-title":"Suppressed smooth muscle proliferation and inflammatory cell invasion after arterial injury in elafin-overexpressing mice","volume":"105","author":"Zaidi","year":"2000","journal-title":"J. Clin. Invest."},{"key":"2021111900514075900_B23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.biochi.2007.10.009","article-title":"Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions","volume":"90","author":"Korkmaz","year":"2008","journal-title":"Biochimie"},{"key":"2021111900514075900_B24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1286-4579(02)01654-4","article-title":"Neutrophil elastase-mediated killing of bacteria: lessons from targeted mutagenesis","volume":"4","author":"Belaaouaj","year":"2002","journal-title":"Microbes Infect."},{"key":"2021111900514075900_B25","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1172\/JCI109926","article-title":"Chemotactic activity of elastin-derived peptides","volume":"66","author":"Senior","year":"1980","journal-title":"J. Clin. Invest."},{"key":"2021111900514075900_B26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1189\/jlb.0203086","article-title":"Proteinase-3 directly activates MMP-2 and degrades gelatin and Matrigel; differential inhibition by (\u2212)epigallocatechin-3-gallate","volume":"74","author":"Pezzato","year":"2003","journal-title":"J. Leukocyte Biol."},{"key":"2021111900514075900_B27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0014-5793(96)01508-6","article-title":"Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury","volume":"402","author":"Ferry","year":"1997","journal-title":"FEBS Lett."},{"key":"2021111900514075900_B28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0014-5793(03)00482-4","article-title":"Neutrophil elastase up-regulates interleukin-8 via Toll-like receptor 4","volume":"544","author":"Devaney","year":"2003","journal-title":"FEBS Lett."},{"key":"2021111900514075900_B29","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.4049\/jimmunol.175.11.7594","article-title":"Viral inhibition of IL-1- and neutrophil elastase-induced inflammatory responses in bronchial epithelial cells","volume":"175","author":"Carroll","year":"2005","journal-title":"J. Immunol."},{"key":"2021111900514075900_B30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-3083.2006.01772.x","article-title":"Induction of interleukin-6 release from monocytes by serine proteinases and its potential mechanisms","volume":"64","author":"Li","year":"2006","journal-title":"Scand. J. Immunol."},{"key":"2021111900514075900_B31","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.1073\/pnas.96.11.6261","article-title":"Converting enzyme-independent release of tumor necrosis factor \u03b1 and IL-1\u03b2 from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3","volume":"96","author":"Coeshott","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111900514075900_B32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0014-5793(94)00952-X","article-title":"Interleukin-8 processing by neutrophil elastase, cathepsin G and proteinase-3","volume":"352","author":"Padrines","year":"1994","journal-title":"FEBS Lett."},{"key":"2021111900514075900_B33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0014-5793(99)00670-5","article-title":"Elafin (elastase-specific inhibitor) has anti-microbial activity against Gram-positive and Gram-negative respiratory pathogens","volume":"452","author":"Simpson","year":"1999","journal-title":"FEBS Lett."},{"key":"2021111900514075900_B34","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1111\/j.1742-4658.2008.06355.x","article-title":"The antibacterial and antifungal properties of trappin-2 (pre-elafin) do not depend on its protease inhibitory function","volume":"275","author":"Baranger","year":"2008","journal-title":"FEBS J."},{"key":"2021111900514075900_B35","doi-asserted-by":"crossref","first-page":"34730","DOI":"10.1074\/jbc.M604844200","article-title":"Elafin prevents lipopolysaccharide-induced AP-1 and NF-\u03baB activation via an effect on the ubiquitin-proteasome pathway","volume":"281","author":"Butler","year":"2006","journal-title":"J. Biol. Chem."},{"key":"2021111900514075900_B36","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1165\/rcmb.2004-0250OC","article-title":"The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses","volume":"32","author":"McMichael","year":"2005","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2021111900514075900_B37","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/QAD.0b013e32832ea643","article-title":"Elevated elafin\/trappin-2 in the female genital tract is associated with protection against HIV acquisition","volume":"23","author":"Iqbal","year":"2009","journal-title":"AIDS"},{"key":"2021111900514075900_B38","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1172\/JCI5099","article-title":"Targeted overexpression of elafin protects mice against cardiac dysfunction and mortality following viral myocarditis","volume":"103","author":"Zaidi","year":"1999","journal-title":"J. Clin. Invest."},{"key":"2021111900514075900_B39","doi-asserted-by":"crossref","first-page":"H286","DOI":"10.1152\/ajpheart.00479.2002","article-title":"Elafin-overexpressing mice have improved cardiac function after myocardial infarction","volume":"287","author":"Ohta","year":"2004","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021111900514075900_B40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/01.CIR.102.suppl_3.III-289","article-title":"Gene transfer of the serine elastase inhibitor elafin protects against vein graft degeneration","volume":"102","author":"O'Blenes","year":"2000","journal-title":"Circulation"},{"key":"2021111900514075900_B41","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/hq0801.093589","article-title":"Arterial elastase activity after balloon angioplasty and effects of elafin, an elastase inhibitor","volume":"21","author":"Barolet","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021111900514075900_B42","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1177\/096721099400200614","article-title":"Role of neutrophil depletion and elastase inhibition in modifying skeletal muscle reperfusion injury","volume":"2","author":"Crinnion","year":"1994","journal-title":"Cardiovasc. Surg."},{"key":"2021111900514075900_B43","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s004240050315","article-title":"Inhibition of elastase improves myocardial function after repetitive ischaemia and myocardial infarction in the rat heart","volume":"433","author":"Tiefenbacher","year":"1997","journal-title":"Pfl\u00fcgers Arch."},{"key":"2021111900514075900_B44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/1043-4666(94)90040-X","article-title":"Elevation of circulating interleukin 6 after surgery: factors influencing the serum level","volume":"6","author":"Sakamoto","year":"1994","journal-title":"Cytokine"},{"key":"2021111900514075900_B45","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0003-4975(01)03584-6","article-title":"Pulmonary complications after esophagectomy","volume":"73","author":"Avendano","year":"2002","journal-title":"Ann. Thorac. Surg."},{"key":"2021111900514075900_B46","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/PL00012432","article-title":"Magnitude of the inflammatory response to cardiopulmonary bypass and its relation to adverse clinical outcomes","volume":"51","author":"Holmes","year":"2002","journal-title":"Inflamm. Res."},{"key":"2021111900514075900_B47","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1111\/j.1523-1755.2000.00390.x","article-title":"Ischemia\u2013reperfusion injury in renal transplantation is independent of the immunologic background","volume":"58","author":"Dragun","year":"2000","journal-title":"Kidney Int."},{"key":"2021111900514075900_B48","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1093\/ndt\/gfq041","article-title":"Plasma and urine leukocyte elastase-\u03b11 protease inhibitor complex as a marker of early and long-term kidney graft function","volume":"25","author":"Zynek-Litwin","year":"2010","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["Biochemical Society Transactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/39\/5\/1450\/551384\/bst0391450.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/39\/5\/1450\/551384\/bst0391450.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T03:19:03Z","timestamp":1743045543000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article\/39\/5\/1450\/86612\/Therapeutic-potential-of-human-elafin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,21]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,9,21]]},"published-print":{"date-parts":[[2011,10,1]]}},"URL":"https:\/\/doi.org\/10.1042\/bst0391450","relation":{},"ISSN":["0300-5127","1470-8752"],"issn-type":[{"value":"0300-5127","type":"print"},{"value":"1470-8752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,21]]}}}